Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1998-07-21
2000-05-02
Brusca, John S.
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
536231, 536 243, 536 2431, 435325, 435366, 435375, 514 44, C07H 2104, C12N 1511, C12N 1585, A61K 4800
Patent
active
060574372
ABSTRACT:
The present invention provides an antisense nucleic acid compound inhibiting expression of vascular endothelial growth factor as well as therapeutic and diagnostic agents comprising the same as an active ingredient. A compound which nucleotide sequence is substantially complementary to a nucleotide sequence located upstream of a translation region in a gene coding for vascular endothelial growth factor and which inhibits 50% or more of the expression of vascular endothelial growth factor in cells is used as the antisense nucleic acid.
REFERENCES:
patent: 5639736 (1997-06-01), Robinson
patent: 5639872 (1997-06-01), Robinson
Crooke, S.T. Chapter 1 in "Antisense Research and Application", Stanley T. Crooke, ed., pp. 1-50 (Springer-Verlag, New York, 1998).
Branch, A.D. TIBS. Feb. 1998, vol. 23, pp. 45-50.
Gewirtz, A.M. et al. Proc. Natl. Acad. Sci. USA. Apr. 1996, vol. 93, pp. 3161-3163, Apr. 1998.
Rojanasakul, Y. Advanced Drug Delivery Reviews. Jan. 1996, vol. 18, pp. 115-131.
Kamiya Kinya
Matsuda Yoko
Uchida Kiyoshi
Brusca John S.
Shibuya Mark L.
Taogosei Co. Ltd.
LandOfFree
Antisense nucleic acid compounds inhibiting vascular endothelial does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense nucleic acid compounds inhibiting vascular endothelial, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense nucleic acid compounds inhibiting vascular endothelial will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1594894